Influence of drugs on vitamin D and calcium metabolism

References

• McCollum EF, Simmonds N, Becker JE, Shipley PG. Studies on experimental rickets and experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922; 53:293 - 312; PMID: 11991957
   PubMedGoogle Scholar
• Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 2004; 134:1299 - 302; PMID: 15173387
   PubMed Web of Science ®Google Scholar
• Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266 - 81; http://dx.doi.org/10.1056/NEJMra070553; PMID: 17634462
   PubMed Web of Science ®Google Scholar
• Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 2008; 87:suppl 1080S - 6S; PMID: 18400738
   PubMed Web of Science ®Google Scholar
• Bartl R, Bartl C, Gradinger R. [Drug-induced osteopathies. Drugs, pathogenesis, forms, diagnosis, prevention and therapy]. Z Rheumatol 2010; 69:135 - 50, quiz 151; PMID: 20146045
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Robert A, Nguyen M, Walrant-Debray O, Garabedian M, Martin P, et al. Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 2005; 115:177 - 86; PMID: 15630458
   PubMed Web of Science ®Google Scholar
• Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest 2005; 115:32 - 4; PMID: 15630441
   PubMed Web of Science ®Google Scholar
• Gröber U, Holick MF, Kisters K. [Vitamin D and drugs]. Med Monatsschr Pharm 2011; 34:377 - 87; PMID: 22010421
   PubMedGoogle Scholar
• Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. [Epub ahead of print] Osteoporos Int 2012; http://dx.doi.org/10.1007/s00198-011-1868-7; PMID: 22237813
   PubMed Web of Science ®Google Scholar
• Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin D levels and lipid response to atorvastatin. Int J Endocrinol, 2010; 2010:320721.
   Google Scholar
• Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377:242 - 50; http://dx.doi.org/10.1016/S0140-6736(10)61889-2; PMID: 21215445
   PubMed Web of Science ®Google Scholar
• Zhang B, Xie W, Krasowski MD. PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 2008; 9:1695 - 709; http://dx.doi.org/10.2217/14622416.9.11.1695; PMID: 19018724
   PubMed Web of Science ®Google Scholar
• Dent CE, Richens A, Rowe DJ, Stamp TC. Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 1970; 4:69 - 72; http://dx.doi.org/10.1136/bmj.4.5727.69; PMID: 5312062
   PubMed Web of Science ®Google Scholar
• Petty SJ, O’Brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007; 18:129 - 42; http://dx.doi.org/10.1007/s00198-006-0185-z; PMID: 17091219
   PubMed Web of Science ®Google Scholar
• Valsamis HA, Arora SK, Labban B, McFarlane SI. Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) 2006; 3:36; http://dx.doi.org/10.1186/1743-7075-3-36; PMID: 16956398
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004; 45:1330 - 7; http://dx.doi.org/10.1111/j.0013-9580.2004.18804.x; PMID: 15509233
   PubMed Web of Science ®Google Scholar
• Gröber U, Arzneimittel und Mikronährstoffe. Medikationsorientierte Supplementierung. 2. Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 2012.
   Google Scholar
• Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19:893 - 9; http://dx.doi.org/10.1359/JBMR.040134; PMID: 15125788
   PubMed Web of Science ®Google Scholar
• Dachverband Osteologie e.V. (DVO). Prophylaxe, Diagnostik und Therapie der Glukokortikoid-induzierten Osteoporose (2006) bei Erwachsenen (2006)
   Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15:993 - 1000; http://dx.doi.org/10.1359/jbmr.2000.15.6.993; PMID: 10841167
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48:3224 - 9; http://dx.doi.org/10.1002/art.11283; PMID: 14613287
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 2000; 9:359 - 66; http://dx.doi.org/10.1002/1099-1557(200009/10)9:5<359::AID-PDS507>3.0.CO;2-E; PMID: 19025840
   PubMed Web of Science ®Google Scholar
• Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. Z Rheumatol 2000; 59:Suppl 1 48 - 52; http://dx.doi.org/10.1007/s003930070040; PMID: 10769437
   PubMedGoogle Scholar
• Allen AC, Kelly S, Basdeo SA, Kinsella K, Mulready KJ, Mills KH, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. [Epub ahead of print] Mult Scler 2012; http://dx.doi.org/10.1177/1352458512442992; PMID: 22457344
   PubMed Web of Science ®Google Scholar
• Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, et al. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis. [Epub ahead of print] J Neurol Neurosurg Psychiatry 2012; 83:565 - 71; http://dx.doi.org/10.1136/jnnp-2011-301876; PMID: 22362918
   PubMed Web of Science ®Google Scholar
• Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169:384 - 90; http://dx.doi.org/10.1001/archinternmed.2008.560; PMID: 19237723
   PubMed Web of Science ®Google Scholar
• Brehm JM, Schuemann B, Fuhlbrigge AL, Hollis BW, Strunk RC, Zeiger RS, et al, Childhood Asthma Management Program Research Group. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126:52 - 8, e5; http://dx.doi.org/10.1016/j.jaci.2010.03.043; PMID: 20538327
   PubMed Web of Science ®Google Scholar
• Searing DA, Zhang Y, Murphy JR, Hauk PJ, Goleva E, Leung DY. Decreased serum vitamin D levels in children with asthma are associated with increased corticosteroid use. J Allergy Clin Immunol 2010; 125:995 - 1000; http://dx.doi.org/10.1016/j.jaci.2010.03.008; PMID: 20381849
   PubMed Web of Science ®Google Scholar
• Bozzetto S, Carraro S, Giordano G, Boner A, Baraldi E. Asthma, allergy and respiratory infections: the vitamin D hypothesis. Allergy 2012; 67:10 - 7; http://dx.doi.org/10.1111/j.1398-9995.2011.02711.x; PMID: 21933195
   PubMed Web of Science ®Google Scholar
• Berruti A, et al. Effect of zoledronic acid (z) treatment based on serum parathyroid hormone (pth) levels in patients (pts) with malignant bone disease. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement): abstract 8610.
   Google Scholar
• Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?. Ann Oncol 2006; 17:1336 - 7; http://dx.doi.org/10.1093/annonc/mdl045; PMID: 16524968
   PubMed Web of Science ®Google Scholar
• Deane A, Constancio L, Fogelman I, Hampson G. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis. BMC Musculoskelet Disord 2007; 8:3; http://dx.doi.org/10.1186/1471-2474-8-3; PMID: 17214897
   PubMed Web of Science ®Google Scholar
• Adami S, Giannini S, Bianchi G, Sinigaglia L, Di Munno O, Fiore CE, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20:239 - 44; http://dx.doi.org/10.1007/s00198-008-0650-y; PMID: 18551242
   PubMed Web of Science ®Google Scholar
• Bruyère O, Reginster JY. Vitamin D status and response to antiosteoporotic therapy. [London Engl] Womens Health (Lond Engl) 2008; 4:445 - 7; http://dx.doi.org/10.2217/17455057.4.5.445; PMID: 19072484
   PubMedGoogle Scholar
• Ginde AA, Wolfe P, Camargo CA Jr., Schwartz RS. Defining vitamin D status by secondary hyperparathyroidism in the U.S. population. J Endocrinol Invest 2012; 35:42 - 8; PMID: 21606669
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165 - 74; http://dx.doi.org/10.1097/QAD.0b013e32801022eb; PMID: 17086056
   PubMed Web of Science ®Google Scholar
• Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010; 54:123 - 32; http://dx.doi.org/10.1590/S0004-27302010000200007; PMID: 20485900
   PubMed Web of Science ®Google Scholar
• Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther 2011; 16:1063 - 72; http://dx.doi.org/10.3851/IMP1874; PMID: 22024522
   PubMed Web of Science ®Google Scholar
• Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24:1923 - 8; http://dx.doi.org/10.1097/QAD.0b013e32833c3281; PMID: 20588161
   PubMed Web of Science ®Google Scholar
• Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24:1375 - 82; http://dx.doi.org/10.1089/aid.2008.0058; PMID: 18928396
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348:2431 - 42; http://dx.doi.org/10.1056/NEJMra023246; PMID: 12802030
   PubMed Web of Science ®Google Scholar
• Servitja S, Nogués X, Prieto-Alhambra D, Martínez-García M, Garrigós L, Peña MJ, et al. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer. Breast 2012; 21:95 - 101; http://dx.doi.org/10.1016/j.breast.2011.09.001; PMID: 21924904
   PubMed Web of Science ®Google Scholar
• Khan QJ, O'Dea AP, Sharma P, Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol, 2010; 2010. pii: 654348.
   Google Scholar
• Aktories K, Förstermann U, Hofmann FB, Starke K, eds. Allgemeine und spezielle Pharmakologie und Toxikologie. 10. Auflage. München: Elsevier, Urban & Fischer, 2009.
   Google Scholar
• Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, et al. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48:417 - 28; http://dx.doi.org/10.1016/0092-8674(87)90193-0; PMID: 2879636
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14:78 - 84; PMID: 8558225
   PubMed Web of Science ®Google Scholar
• Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, nonspecific musculoskeletal pain. Mayo Clin Proc 2003; 78:1463 - 70; http://dx.doi.org/10.4065/78.12.1463; PMID: 14661675
   PubMed Web of Science ®Google Scholar
• Lønning PE. Bone safety of aromatase inhibitors versus tamoxifen. Int J Gynecol Cancer 2006; 16:Suppl 2 518 - 20; http://dx.doi.org/10.1111/j.1525-1438.2006.00685.x; PMID: 17010062
   PubMedGoogle Scholar
• Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int 1986; 39:139 - 44; http://dx.doi.org/10.1007/BF02555109; PMID: 3093024
   PubMed Web of Science ®Google Scholar
• Cheema C, Grant BF, Marcus R. Effects of estrogen on circulating “free” and total 1,25-dihydroxyvitamin D and on the parathyroid-vitamin D axis in postmenopausal women. J Clin Invest 1989; 83:537 - 42; http://dx.doi.org/10.1172/JCI113915; PMID: 2492309
   PubMed Web of Science ®Google Scholar
• Gilad LA, Bresler T, Gnainsky J, Smirnoff P, Schwartz B. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol 2005; 185:577 - 92; http://dx.doi.org/10.1677/joe.1.05770; PMID: 15930183
   PubMed Web of Science ®Google Scholar
• Escaleira MT, Sonohara S, Brentani MM. Sex steroids induced up-regulation of 1,25-(OH)2 vitamin D3 receptors in T 47D breast cancer cells. J Steroid Biochem Mol Biol 1993; 45:257 - 63; http://dx.doi.org/10.1016/0960-0760(93)90340-3; PMID: 8388708
   PubMed Web of Science ®Google Scholar
• Prieto-Alhambra D, Javaid MK, Servitja S, Arden NK, Martinez-García M, Diez-Perez A, et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 2011; 125:869 - 78; http://dx.doi.org/10.1007/s10549-010-1075-9; PMID: 20665105
   PubMed Web of Science ®Google Scholar
• Khan QJ, Reddy PS, Kimler BF, Sharma P, Baxa SE, O’Dea AP, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119:111 - 8; http://dx.doi.org/10.1007/s10549-009-0495-x; PMID: 19655244
   PubMed Web of Science ®Google Scholar
• Khan QJ, Kimler BF, Fabian CJ. The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 2010; 12:136 - 42; http://dx.doi.org/10.1007/s11912-010-0081-8; PMID: 20425599
   PubMedGoogle Scholar
• Freedman DM, Looker AC, Chang SC, Graubard BI. Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 2007; 99:1594 - 602; http://dx.doi.org/10.1093/jnci/djm204; PMID: 17971526
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27:3757 - 63; http://dx.doi.org/10.1200/JCO.2008.20.0725; PMID: 19451439
   PubMed Web of Science ®Google Scholar
• Santini D, Galluzzo S, Vincenzi B, Zoccoli A, Ferraro E, Lippi C, et al. Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 2010; 21:185 - 6; http://dx.doi.org/10.1093/annonc/mdp497; PMID: 19892747
   PubMed Web of Science ®Google Scholar
• Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29:e81 - 2; http://dx.doi.org/10.1200/JCO.2010.31.5317; PMID: 21060025
   PubMedGoogle Scholar
• Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens 2009; 27:1948 - 54; http://dx.doi.org/10.1097/HJH.0b013e32832f075b; PMID: 19587609
   PubMed Web of Science ®Google Scholar
• Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229 - 38; PMID: 12122115
   PubMed Web of Science ®Google Scholar
• Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003; 88:327 - 31; http://dx.doi.org/10.1002/jcb.10343; PMID: 12520534
   PubMed Web of Science ®Google Scholar
• Gupta AK, Sexton RC, Rudney H. Effect of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells. J Lipid Res 1989; 30:379 - 86; PMID: 2542424
   PubMed Web of Science ®Google Scholar
• Pérez-Castrillón JL, Abad Manteca L, Vega G, Del Pino Montes J, de Luis D, Duenas Laita A. Vitamin d levels and lipid response to atorvastatin. Int J Endocrinol 2010; 2010:320721; http://dx.doi.org/10.1155/2010/320721; PMID: 20016682
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Budhani SB, Masineni SS, Abuchaibe C, Khan N, Wang P, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin 2011; 27:1683 - 90; http://dx.doi.org/10.1185/03007995.2011.598144; PMID: 21728907
   PubMed Web of Science ®Google Scholar
• Ahmed W, Khan N, Glueck CJ, Pandey S, Wang P, Goldenberg N, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res 2009; 153:11 - 6; http://dx.doi.org/10.1016/j.trsl.2008.11.002; PMID: 19100953
   PubMed Web of Science ®Google Scholar
• Zhou C, Verma S, Blumberg B. The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 2009; 7:e001; PMID: 19240808
   PubMedGoogle Scholar
• Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 2006; 116:1703 - 12; http://dx.doi.org/10.1172/JCI27793; PMID: 16691293
   PubMed Web of Science ®Google Scholar